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Introduction
　Factor Ⅶ（FⅦ）deﬁ ciency is a rare congenital coagu-
lation disorder displaying an autosomal recession inher-
itance pattern1 with a population incidence reported at 
1 in 500,0002.  Replacement therapy is required for the 
treatment of bleeding.  Recently, recombinant activated 
factor Ⅶ（rFⅦa）has been introduced for the treatment 
of hemophiliac patients with inhibitors.  We report our 
experience of successful hemostasis after dental extrac-
tion with the use of rFⅦa in a FⅦ deﬁ cient patient.
Case Report
　A 17-year-old girl was referred for gingival bleeding 
in March 1990.  She had a history of recurrent epistaxis 
and postoperative bleeding episodes after dental extrac-
tions of deciduous teeth.  Her mother and elder sister 
had a history suggestive of bleeding diathesis.  She was 
pale, and moderate bleeding was observed in her left 
upper premolar gingiva.  Screening tests to determine 
bleeding propensity revealed prolonged prothrombin 
time（PT; PT%＝25%）and normal activated partial 
thromboplastin time（APTT; 31.8 sec）.
　Coagulation factors were checked, and the activity of 
FⅦ was 4%, signiﬁ cantly reduced.  The activity of FⅦ in 
her family members was 54% in her father, 76% in her 
mother and 77% in her elder sister, establishing the di-
agnosis of congenital FⅦ deﬁ ciency4.  Her ﬁ rst admis-
sion was on July 1990.  In order to control the inﬂ am-
mation of her gingiva, she underwent root scaling. 
Local application of thrombin（5000 U）and compres-
sion with a dental appliance for 5 days was able to re-
strain the bleeding.  Thereafter, periodical follow-ups 
were continued to keep her oral hygiene good.  In No-
vember 1997, she delivered a baby by an abdominal ce-
sarean section.  Preoperatively 800 U of factor Ⅸ com-
plex concentrate（Proplex STⓇ, Baxter）was admini-
stered.  After childbirth she could not visit our clinic. 
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On May 2003, she visited complaining of gingival bleed-
ing again.  The periodontal pockets of her molar teeth 
were 3‒5 mm, and she bled when brushing.  She under-
went root scaling of all teeth and gingival curettage on 
her molar teeth.  After dental procedures, bleeding 
could be controlled by local application of thrombin
（5000 U）and compression with a dental appliance.  On 
September 2004, pericoronitis of the lower right wisdom 
tooth could not be controlled, and continuous pain and 
pus discharge were observed.  As the tooth was the 
backmost molar, it was thought that compression with a 
dental appliance after tooth extraction might not be a 
reliable approach, so the preoperative replacement with 
rFⅦa（NovosevenⓇ, Novo Nordisk）was planned.  It 
was arranged to administer rFⅦa by intravenous bolus 
injection of the dose 20μg/ kg, 30 min before tooth ex-
traction followed by a half dose every 6 hours until he-
mostasis was achieved.  Preoperative PT% was 25%, 
and FⅦ was less than 3%.  Thirty minutes before tooth 
extraction, 1.2 mg of rFⅦa was injected.  At the begin-
ning of the operation, PT% was more than 200%, FⅦ 
was 336%（Table 1）, and the hemostasis after dental 
extraction was excellent（Fig. 1）.  FⅦ was 61% even 6 
hours after operation and no postoperative bleeding was 
observed, so additional administration was not neces-
sary.
Discussion
　In patients with FⅦ deﬁ ciency, the symptoms most 
frequently reported are recurrent epistaxis and moder-
ate delayed bleeding after dental extraction.  Epistaxis 
is the most common hemorrhagic manifestation2.
　The diagnosis of FⅦ deﬁ ciency is suggested by a pro-
longed PT with a normal APTT.  No other congenital co-
agulation disorders have a similar pattern.  If hepatic 
dysfunction and vitamin K deﬁ ciency are not present, 
deﬁ nitive diagnosis can be made by the speciﬁ c assay of 
FⅦ.  Replacement therapy is required for the manage-
ment of severe to moderate bleeding.  Prothrombin com-
plex concentrates or activated prothrombin complex 
concentrates have been used.  However, these concen-
trates have serious disadvantages.  First, the risk of 
thrombotic complications causes an unnecessary rise in 
the vitamin K dependent factors.  Second, using blood 
donor products carries the risk of human viral trans-
mission.
　Recently, the rFⅦa preparation（NovosevenⓇ, Novo 
Nordisk）was developed as a second-generation by-
passing material intended mainly for use in hemophilia 
patients with inhibitors3.  The process is independent of 
the presence of factors Ⅷ or Ⅸ and is not affected by in-
hibitors4.  As human plasma contains only a low level of 
FⅦ, this drug was produced using a genetically modiﬁ ed 
technique.  Compared with the concentrates from hu-
man plasma, when the rFⅦa is applied to patients suf-
fering from FⅦ deﬁ ciency, it reduces the risk of throm-
botic complaints because it is inactive in the blood 
circulation, is activated only after arrival at the injured 
lesion, and it does not activate the other vitamin K de-
pendent factors3,4.  Though several articles have been 
published regarding the use of rFⅦa for the treatment 
of FⅦ deﬁ ciency, there are no reports about disadvan-
tages except for one case.  In that case, antibodies to FⅦ 
appeared 4‒5 weeks after the administration of a dose, 
by mistake, which was 40 times higher than the aver-
age effective dose3.
　The half life of FⅦ has been determined as 3.5 hours5, 
but in vivo it is reported to range from 5.3 hours6 to 6 
hours7.  According to the report about FⅦ after intrave-
nous bolus injection of rFⅦa, the activity was at its 
maximum during the ﬁ rst 30 min, and was completed 
Table 1　PT% and FⅦ activity in response to rFⅦa infusion
Time after infusion（hrs） 0 0.5 6 24
PT%（%） 25 ＞ 200 112 27
FⅦ activity（%） ＜ 3 336 61 ＜ 3
Fig. 1 Intraoral view after dental extraction of 
lower right wisdom tooth. The hemostasis is 
excellent.
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within 6 hours1,7.  In our case, only a single use of 20μg/
kg, 30 min before surgery raised the FⅦ level to 336% 
at dental extraction and it stayed at 61% even 6 hours 
after.  Mariani et al.3 summarized the median dose of rF
Ⅶa to normalize the mean PT ratio as 25.66μg/kg in 
their 17 FⅦ deﬁ cient patients.  It is generally agreed 
that surgical intervention will cause bleeding in pa-
tients with FⅦ levels below 10‒15%8 of normal, and lev-
els of 15‒25% are thought to be sufﬁ cient for normal he-
mostasis9.  The recommended dose range for the 
treatment of bleeding episodes in patients undergoing 
surgery or invasive procedures is 15‒30μg/kg, every 4‒6 
hours until hemostasis is achieved.  The dose and fre-
quency of injections should be adapted to each individu-
al.  In our computer database search, we found only two 
documented cases of the use of rFⅦa for dental extrac-
tions in FⅦ deﬁ cient patients.  In the ﬁ rst case, for ﬁ ve 
teeth extractions, the dosage was 24μg/kg before sur-
gery, repeated after 7 hours, thereafter two doses of 
12μg/kg were administered at 6 hours10.  Based on the 
preliminary experience, it was suggested that further 
reduction of the dosage of rFⅦa could be exploited in 
the setting of minor oral surgery prophylaxis10.  In the 
second case of dental extraction, the dosage was 25μg/
kg, and despite only single use the result was excellent3. 
Our case was treated with 20μg/kg（1.2 mg/body）sin-
gle use 30 min before surgery.  The local hemostasis was 
excellent.
　It is thought that 20μg/kg single use 30 min before 
surgery is enough for the extraction of a few teeth.  Re-
placement therapy by rFⅦa is the ﬁ rst line therapy to 
control bleeding in a situation of spontaneous bleeding 
and in surgical interventions for FⅦ deﬁ ciency, because 
it corrects the clotting default at a low dosage.
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